CSL Ltd., the world’s second-biggest maker of flu shots, forecast a US vaccination rebound as health groups counter misinformation and rising illness rates revive concern about prevention. A recovery ...

Alongside the U.S. government’s overhaul of the federal vaccine infrastructure, influenza vaccination rates in the country have plummeted below the expectations of a key player in the space. That ...

Good morning, ladies and gentlemen. We still have some people registering, but we always start our Board meetings on time at CSL. So today will be no exception. Welcome to CSL's 2025 Annual General ...

CSL is trying hard to reset relations with investors. It has modified revenue and earnings guidance. It has ushered in a new chief financial officer. It is promising to simplify a business that ...

(Reuters) -Australian biotech CSL said on Tuesday it no longer expects to complete the spin-off of its vaccine division in fiscal 2026, citing heightened volatility in the U.S. influenza vaccine ...

Healthcare giant CSL has had a difficult year as operational challenges began to emerge. The company's share price has tumbled significantly since earnings season in August. Three fund managers have ...

The BMW M4 CSL marks a new era of performance and precision. Lighter, sharper, and more focused than the M4 Competition, it’s the most powerful M car ever built for the road. In this in-depth look, we ...

CSL faces the prospect of a second strike in two years this week when the board fronts angry investors after a poorly received restructure wiped billions of dollars from the biotechnology giant’s ...

This video features a quarter-mile drag race between the BMW M3 CSL E46 and the VW Bora VR6. Both cars showcase their acceleration and engine sound on the straight line, highlighting the differences ...

Let's see what two leading analysts are saying about the biotech giant. CSL shares are down 40% year-to-date after experiencing a further 5% drop today. Bell Potter maintains a hold rating with a ...

Australia's CSL is wielding the axe, cutting its workforce by 15% – around 3,000 positions – while announcing plans to spin its vaccines unit into a standalone company. The decision to demerge the CSL ...